Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, Zhang Y, Meng L, Zhu H, Du X, Chen S, Liang Y, Hu Y, Liu X, Song Y, Men L, Chen Z, Niu Q, Wang H, Lu M, Yang D, Zhai Y, Huang X.
Jiang Q, et al. Among authors: qin y.
J Hematol Oncol. 2022 Oct 31;15(1):159. doi: 10.1186/s13045-022-01369-2.
J Hematol Oncol. 2022.
PMID: 36316695
Free PMC article.
No abstract available.